

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

SdhA interferes with disruption of the *Legionella*-containing vacuole by hijacking the OCRL phosphatase

Won Young Choi¹, Elizabeth A. Creasey^{1,3}, Martin Lowe² and Ralph R. Isberg^{1,4}

¹Department of Molecular Biology and Microbiology, Tufts University School of Medicine, 150 Harrison Ave., Boston, MA 02111, USA.

²School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, Manchester, M13 9PT, United Kingdom

³Current Address: Center for Computational and Integrative Biology, MGH, Boston, MA, USA

⁴Correspondence: Ralph R. Isberg, Tufts University School of Medicine, 150 Harrison Ave., Boston, MA 02111, United States, email: ralph.isberg@tufts.edu, Phone: 617-636-3993

26 **Summary**

27 *Legionella pneumophila* grows intracellularly within a replication vacuole via action of
28 Icm/Dot-secreted proteins. One such protein, SdhA, maintains the integrity of the vacuolar
29 membrane, thereby preventing cytoplasmic degradation of bacteria. We show here that SdhA
30 binds and blocks the action of OCRL (OculoCerebroRenal syndrome of Lowe), an inositol 5-
31 phosphatase pivotal for controlling endosomal dynamics. OCRL depletion resulted in enhanced
32 vacuole integrity and intracellular growth of a *sdhA* mutant, consistent with OCRL participating
33 in vacuole disruption. Overexpressed SdhA altered OCRL function, enlarging endosomes,
34 driving endosomal accumulation of PI(4,5)P₂, and interfering with endosomal trafficking. SdhA
35 interrupted Rab GTPase-OCRL interactions by binding to the OCRL ASH domain, without
36 directly altering OCRL 5-phosphatase activity. The *Legionella* vacuole encompassing the *sdhA*
37 mutant accumulated OCRL and endosomal antigen EEA1, consistent with SdhA blocking
38 accumulation of OCRL-containing endosomal vesicles. Therefore, SdhA hijacking of OCRL is
39 associated with blocking trafficking events that disrupt the pathogen vacuole.
40

41 **Introduction**

42 *Legionella pneumophila* is the causative agent of the potentially fatal Legionnaire's
43 disease, growing within alveolar macrophages as a central step in its pathogenesis (Copenhaver
44 et al., 2014; Nash et al., 1984). As an environmental bacterium, the primary selective force for
45 intracellular growth is its ability to infect amoebae, which can contaminate a variety of plumbing
46 and cooling systems that act as disease reservoirs (Muder et al., 1986; Rowbotham, 1980).
47 Human infection occurs by accidental inhalation or aspiration of contaminated aerosolized water
48 followed by intracellular growth of *Legionella* in alveolar macrophages (Horwitz and Silverstein,
49 1980).

50 The intracellular growth of *L. pneumophila* depends on the construction of the
51 *Legionella*-containing vacuole (LCV). Once internalized, the bacterium translocates about 300
52 bacterial proteins into the host via the Icm/Dot Type IV secretion system (T4SS) (Huang et al.,
53 2011; Luo and Isberg, 2004; Zhu et al., 2011). The secretion of bacterial effector proteins into
54 the host cell allows hijacking of host membrane trafficking pathways to remodel the LCV into a
55 membranous compartment that supports intracellular replication (Berger and Isberg, 1993; Segal,
56 2013; Segal and Shuman, 1999). In contrast to phagocytic uptake of nonpathogens, which is
57 characterized by interactions with the endocytic pathway and subsequent targeting to lysosomal
58 compartments, the LCV recruits components of the early secretory pathway, allowing direct
59 interaction with the endoplasmic reticulum (ER) (Clemens et al., 2000; Kagan and Roy, 2002;
60 Swanson and Isberg, 1995; Tilney et al., 2001). This ER-encompassed compartment, protected
61 from lysosomal degradation, also sequesters the bacterium from the cytoplasmic innate immune
62 sensing system in mammalian hosts. The extreme restriction of bacteria that enter the
63 mammalian cell cytosol was first demonstrated by the behavior of *L. pneumophila sdhA* mutants,

64 which have disrupted vacuoles that result in bacterial exposure to the host cytosol (Aachoui et
65 al., 2013; Creasey and Isberg, 2012; Ge et al., 2012).

66 The SdhA protein is a T4SS substrate essential for intracellular growth of *L. pneumophila*
67 in primary macrophages (Laguna et al., 2006). Release of bacteria into the mammalian cytosol in
68 the absence of SdhA occurs via an unknown pathway, and results in recognition by cytosol-
69 localized interferon (IFN)-stimulated anti-microbial GBPs (Guanylate Binding Proteins) leading
70 to bacterial degradation (Liu et al., 2018; Pilla et al., 2014). The degraded bacteria release
71 bacterial components such as LPS and DNA, which in turn activate AIM2, caspase-11, and
72 caspase-1 inflammasomes causing pyroptotic death of the infected host cells (Creasey and
73 Isberg, 2012; Ge et al., 2012; Pilla et al., 2014). Therefore, even if the vacuole avoids entry into
74 the lysosomal pathway, disruption of the vacuole can lead to cytosolic bacterial degradation.
75 RNAi depletion of Rab5, Rab11, and Rab8, all GTPases involved in endocytic and recycling
76 pathways, partially reverses loss of vacuole integrity observed in *sdhA* mutants. Consistent with
77 these results, the absence of SdhA results in LCV accumulation of EEA1 and Rab11FIP1,
78 downstream effectors of these GTPases (Anand et al., 2020; Christoforidis et al., 1999; Hales et
79 al., 2001). Therefore, it is likely that SdhA interferes with components of the early endocytic
80 network that are likely to disrupt vacuole integrity.

81 One protein involved in controlling the identities of compartments associated with the
82 endocytic network is OCRL (OculoCerebroRenal syndrome of Lowe), a polyphosphoinositide-5-
83 phosphatase that regulates the dynamics of early and recycling endosomes as well as
84 autophagosome-lysosomal fusion (De Matteis et al., 2017; Sharma et al., 2015). The protein has
85 an N-terminal pleckstrin-homology (PH) domain (Mao et al., 2009), a central 5-phosphatase
86 catalytic core (Tsujiyama et al., 2001), a C-terminal ASH (ASPM–SPD2–Hydin) domain

87 (Erdmann et al., 2007; McCrea et al., 2008), and a catalytically inactive RhoGAP (RhoGTPase
88 activating protein)-like domain (Pirruccello and De Camilli, 2012). The C-terminal RhoGAP-like
89 domain interacts with Rho family GTPases allowing recruitment to actin-rich membrane regions
90 (Faucherre et al., 2005; Faucherre et al., 2003). The ASH/RhoGAP domain of OCRL interacts
91 with the endocytic proteins APPL1 and Ses1 (also called IPIP27), associated with endocytosis
92 and receptor recycling, respectively (Diggins and Webb, 2017; Noakes et al., 2011; Swan et al.,
93 2010). Among the proteins that interact with OCRL, the Rab GTPases, which bind to the ASH
94 domain, are most numerous. Interactions with Rab5 and Rab6 target OCRL to endosomes and
95 the TGN (trans-Golgi network), respectively (Hyvola et al., 2006). Loss of OCRL function
96 increases the amount of PI(4,5)P₂ on endosomes impairing membrane trafficking events such as
97 endocytosis/recycling of multiple classes of receptors and M6PR retrograde trafficking
98 (Vicinanza et al., 2011).

99 Here we demonstrate that SdhA prevents endocytic and recycling vesicles from merging
100 with the LCV by targeting OCRL. We found that *sdhA* mutants accumulate high levels of
101 endocytic/recycling vesicles on the vacuole in an OCRL-dependent manner. In the process,
102 SdhA interrupts OCRL interactions with Rab GTPases.

103

104

105

106

107

108

109 **Results**

110 **SdhA contains multiple eukaryotic protein binding motifs**

111 In search of host targets of SdhA, we found that its amino acid sequence predicted that
112 the protein was connected to control of host cell endocytic dynamics. Sequence analysis found
113 two putative “clathrin box” consensus sequences (Table S1), but also multiple endocytic sorting
114 motifs predicted to bind adaptor complexes AP1, AP2, and AP3 (Table S1) (Edeling et al.,
115 2006), as well as an OCRL-binding F&H motif (FxxxHxxØ) (Ø-bulky hydrophobic). This
116 OCRL-binding motif is found in other endocytosis-associated proteins such as APPL1, Ses1, and
117 Ses2 (latter two also called IPIP27A and IPIP27B; Fig. 1A) (Swan et al., 2010; Erdmann et al.,
118 2007). Interestingly, SdhA and OCRL have similar arrangements of motifs predicting endocytic
119 pathway association (Ungewickell et al., 2004; Mao et al., 2009). Given the presence of a
120 potential OCRL binding site and the presence of an array of sites in SdhA that would direct it
121 towards endocytic transport intermediates, we reasoned that SdhA might associate with OCRL
122 (Fig. 1A). Such association could modulate endocytic processes that threaten the integrity of the
123 *Legionella*-containing vacuole (LCV) (Anand et al., 2020).

124

125 **SdhA interacts with OCRL**

126 To determine if SdhA binds OCRL, we first performed co-immunoprecipitation (IP) with
127 extracts of HEK cells transfected with HA-mCherry-tagged SdhA. The tagged SdhA construct
128 quantitatively coprecipitated OCRL as well as the AP complex beta subunit when compared to
129 mCherry alone, although the input level of HA-mCherry-SdhA was much lower relative to the
130 mCherry-HA control (Fig. 1B). Normalizing for relative abundance of the HA tagged proteins
131 present after immunoprecipitation compared to the input samples, association of OCRL with

132 HA-mCherry-SdhA was approximately 27.5-fold above the control (Fig. 1B bottom left). SdhA
133 also pulled down the AP complex beta subunit with similar efficiency (29.5-fold above control),
134 albeit with higher nonspecific binding (Fig. 1B bottom right). Binding to clathrin was
135 inconclusive due to nonspecific binding to mCherry (data not shown). Based on the strong
136 interaction with OCRL, and potential for SdhA targeting an important regulatory protein
137 involved in multiple endocytic paths, we dissected the interface between these two proteins
138 further, and investigated its biological significance.

139 The interaction between SdhA and OCRL was tested using GST pull-down experiments.
140 GST-tagged SdhA fragments were coupled to glutathione beads and incubated with extracts of
141 HEK cells expressing either GFP-tagged full length OCRL or GFP. To this end, SdhA fragments
142 containing either N-terminal motifs (Clathrin Box and AP complex binding Motif; CBM1) or C-
143 terminal motifs (Clathrin Box and F&H Motif; CBM2) were tested for binding (Fig. 1A; CBM1,
144 350-402aa; CBM2, 1029-1260aa). The C-terminal GST-SdhA-CBM2 fragment bound to GFP-
145 OCRL, but not GFP (Fig. 1C). The GFP-OCRL association with SdhA-CBM2 was about 47-fold
146 above the control GST protein. In contrast, SdhA-CBM1 showed no binding to OCRL. The
147 conserved amino acid peptide containing F&H motif (FxxxHxxØ) in Ses or APPL1 was shown
148 to be sufficient for OCRL binding (Swan et al., 2010). However, a GST fusion containing the 13
149 amino acid F&H motif of SdhA did not bind to OCRL (Fig. 1C) and mutations in the putative
150 F&H motif in SdhA-CBM2 did not disrupt OCRL binding (Fig. 1D), indicating that OCRL
151 binding by SdhA is independent of the F&H motif.

152 To discount indirect binding of OCRL to SdhA by a complex series of interactions, we
153 carried out solid-phase binding assays with purified GST-SdhA fragments and the
154 ASH/RhoGAP domain of OCRL (536aa-901aa), the binding region for most of the OCRL

155 partners (Fig. 1A). Direct binding was monitored by incubating increasing amounts of SdhA
156 fragments with plate-immobilized ASH/RhoGAP domain of OCRL, probing with anti-GST.
157 SdhA-CBM2 showed concentration-dependent binding to immobilized ASH/RhoGAP (Fig. 1E).
158 In contrast, neither GST nor GST- CBM1 exhibited binding to ASH/RhoGAP. As predicted from
159 the pulldown assay, binding of a CBM2 Δ F&H motif mutant was equivalent to CBM2,
160 indicating that other sequences are responsible for binding to OCRL, with $EC_{50} = 77.10$ nM and
161 87.43 nM for mutant and WT respectively (Fig. 1E). SdhA binding to OCRL was further tested
162 by competition with the known OCRL-binding F&H motif (13mer) of Ses1 (Swan et al., 2010).
163 Addition of Ses1 F&H motif failed to decrease the binding efficiency of SdhA-CBM2, further
164 arguing that the F&H motif of SdhA is not responsible for binding OCRL (Fig. 1F).

165

166 **Mapping the sites responsible for binding of SdhA and OCRL**

167 Since SdhA does not require the F&H motif for OCRL binding, we searched for the
168 OCRL binding site in SdhA-CBM2. The secondary structure of SdhA-CBM2 is predicted to
169 contain 4 coiled-coils by ncoils (Lupas et al., 1991; Fig. 2A). Based on this prediction, each of
170 the four coils was individually fused to GST and tested for ASH/RhoGAP binding. SdhA-
171 CBM2A, encompassing residues 1029-1080 showed strong binding with the others showing low,
172 but detectable binding to ASH/RhoGAP (Fig. 2B). Moreover SdhA-CBM2A ($EC_{50} \sim 27.2$ nM)
173 showed approximately 3-fold higher binding compared to the full SdhA-CBM2 fragment
174 ($EC_{50} \sim 80.7$ nM) consistent with other regions in SdhA-CBM2 interfering with SdhA-CBM2A
175 binding to OCRL (Fig. 2C). The insolubility of SdhA precluded our ability to purify sufficient
176 quantities to directly test if deletions in the full-length protein blocked binding to OCRL.

177 The RhoGAP domain of OCRL is the target of binding the F&H motifs in Ses and
178 APPL1 (Pirruccello et al., 2011). To test for binding to the complete CBM2 fragment, we
179 separated the ASH domain from the RhoGAP domain, and subjected purified proteins to the
180 solid phase assay. SdhA showed stronger binding to the ASH domain than to the RhoGAP/ASH
181 derivative and, strikingly, there was no detectable binding to the RhoGAP domain (Fig. 2D).
182 Thus, the SdhA-CBM2 fragment binds nearby to the Ses/APPL1 binding region, but not on
183 overlapping sites.

184

185 **The OCRL binding region of SdhA is essential for maintaining LCV integrity and**
186 **promoting intracellular growth**

187 To address the functional importance of SdhA binding to OCRL, we tested for its role in
188 maintaining LCV integrity during bacterial infection by introducing SdhA deletion derivatives
189 on plasmids into a *L. pneumophila* Δ *sdhA* strain. The truncation mutants lacking either CMB2 or
190 CBM2A (Fig. 2A) had no distinguishable effect on growth in culture (Fig. S1A) or on LCV
191 localization based on immunoprobings with SdhA antibody of macrophages after 3hrs incubations
192 (Fig. 3A). Based on Western blot analysis, the expression levels of SdhA mutants were reduced
193 relative to the levels of overproduced plasmid-borne SdhA-FL during *in vitro* growth (Fig. S1B),
194 so their relative localization properties during infection were measured by scoring SdhA
195 positive-LCVs at 4hrs after infection (Fig. S1C). Approximately 90% of LCVs scored positively
196 for SdhA-FL, but none with empty vector indicating the probing is specific. The mutant protein
197 Δ CBM2A showed indistinguishable levels of LCV localization compared to the wild type,
198 although in the Δ CBM2 mutant about 40% of LCVs were positive. In contrast, a WT strain
199 showing endogenous level of SdhA (not overproduced) did not show sufficient expression to

200 detect SdhA using antibody probing. Therefore, even the most poorly expressed plasmid-borne
201 SdhA mutant resulted in levels of LCV localization that were higher than the endogenously-
202 expressed protein.

203 The mutants were next evaluated for vacuole disruption using our previously established
204 immunofluorescence staining, based on antibody accessibility to bacteria in the absence of
205 chemical permeabilization (Creasey and Isberg, 2012). By 8hrs after infection, about 40% of
206 *ΔsdhA*-harboring vacuoles were permeable, compared to approximately 11% for the WT.
207 Complementation of the *ΔsdhA* strain with FL-*sdhA* on the plasmid decreased the vacuole
208 disruption to ~10%, indistinguishable from WT strain Lp02 (Fig. 3B). In contrast, both Δ CBM2
209 and Δ CBM2A showed levels of LCV disruption that were similar to a *ΔsdhA* strain.

210 The loss of vacuole integrity triggered by a *ΔsdhA* strain causes a severe intracellular
211 growth defect (Creasey and Isberg, 2012). As expected, we found that the internal deletions of
212 *sdhA* resulted in growth defects that were indistinguishable from the total *sdhA* deletion strain
213 (Fig. 3C). Taken together, these data are consistent with binding of OCRL by SdhA being tightly
214 linked to maintaining LCV integrity.

215

216 **Ectopically expressed SdhA associates with OCRL-containing vesicles**

217 To determine if SdhA-OCRL binding results in shared distribution through the cell,
218 localization of the two proteins was examined by immunofluorescence microscopy in COS-7
219 cells transfected with mCherry-tagged SdhA and GFP-tagged OCRL. mCherry-SdhA was
220 associated with membranous vesicles, mostly as giant ring-like structures (SdhA in Fig. 4A,
221 SdhA-NOCO in Fig. S2), while mCherry alone localized to the nucleus and cytoplasm (Fig. 4A,
222 CTR in Fig. S2). Surprisingly overexpression of SdhA dramatically altered the distribution of

223 GFP-OCRL. SdhA overexpression caused OCRL aggregation around perinuclear region, with
224 SdhA trapped within the OCRL-positive vacuoles, disturbing OCRL association with the Golgi
225 and its normal association with punctate cytoplasmic vesicles (Fig. 4A, compare mCherry and
226 SdhA). When we treated cells with the microtubule depolymerization drug nocodazole (Fig. S2,
227 +NOCO), the aggregated OCRL-encompassed structures were distributed into small puncta that
228 overlapped with SdhA signal, linking the aberrant morphology to microtubule function.

229

230 **SdhA overproduction phenocopies loss of OCRL function**

231 To investigate whether the aberrant vacuoles generated by SdhA were the result of
232 aggregated endosomes, we probed for endosomal markers in cells overexpressing mCherry-
233 SdhA. Strikingly, SdhA-positive structures adopted unique morphologies, associating with
234 endosomal markers of diverse origins, such as the early endosomal EEA1, late endosomal Rab7,
235 and recycling endosome-derived Rab11 (Fig. 4B). In each case, SdhA redistributed into giant
236 aggregated structures that were enveloped by a mixture of endosomal compartments. The
237 abnormal vacuoles were strongly reminiscent of enlarged endosomal structures observed in cells
238 defective for OCRL function (Vicinanza et al., 2011, Ben El Kadhi et al., 2011). Based on this
239 result, we then determined if SdhA disrupts OCRL control of its preferential substrate,
240 phosphatidylinositol-4,5-bisphosphate (PI(4,5)P₂), and if it interferes with endosomal trafficking.

241 To this end, PI(4,5)P₂ localization was probed using binding by GFP-PLCδ-PH. In
242 control cells, PI(4,5)P₂ associated with the plasma membrane (PM), particularly in regions of
243 ruffling, as previously reported (Watt et al., 2002) (Fig. 4C). Remarkably, with SdhA-transfected
244 cells, we found accumulation of PI(4,5)P₂ on large vacuoles as well as depletion of PI(4,5)P₂ in
245 the PM, indicating dysfunctional PI(4,5)P₂ homeostasis (Fig. 4C; Supplemental Fig. S3). The

246 altered subcellular distribution of PI(4,5)P₂ that we observed appeared to closely phenocopy
247 previous observations in OCRL-depleted cultured mammalian cells, OCRL-depleted *Drosophila*,
248 and OCRL deficient *zebrafish* (Vacinanza et al. 2011, Ben El Kadhi et al. 2011, Ramirez et al.,
249 2012), consistent with SdhA overproduction interfering with OCRL function.

250 It has been reported that OCRL knockdown impairs uptake of transferrin (Tf) and slower
251 recycling of internalized Tf from the PM (Vacinanza et al., 2011). Therefore, to probe for effects
252 of SdhA on endosomal trafficking, recycling of transferrin receptor (TfR) was analyzed in cells
253 overproducing SdhA by measuring internalization or recycling of Alexa488 (A488)-Tf.
254 Compared with mCherry-transfected cells, transfection with SdhA showed a significant defect in
255 uptake of Tf (Fig. 4D). The internalized pool of Tf also showed defective recycling to the PM, as
256 Tf-preloaded cells chased for 1hr in the absence of probe lost approximately 50% of the
257 accumulated Tf in SdhA-transfected cells, while 90% of the probe was lost from the control
258 mCherry-transfected cells during the same time period (Fig. 4E). In addition, Tf accumulated in
259 abnormal aggregated endosomes and was retained in clustered SdhA-containing structures,
260 consistent with SdhA having direct disruptive effects on endosomal dynamics (Fig. 4E).

261

262 **SdhA inhibits Rab5 binding without interfering with the OCRL 5-phosphatase activity**

263 We tested two models for how SdhA could antagonize OCRL function: altering OCRL
264 association with target proteins or its catalytic function. The ASH domain of OCRL binds
265 various Rab GTPases, most notably Rab5, Rab1, and Rab6 (Hyvola et al., 2006). As SdhA also
266 binds to the ASH domain of OCRL, we tested if binding to SdhA fragments could block Rab5
267 association with OCRL. The binding affinities of constitutively active Rab5a (Q79L) and SdhA
268 constructs were first tested, using the solid-phase binding assay in which the ASH/RhoGAP

269 domain of OCRL was immobilized and incubated with increasing amounts of each protein (Fig.
270 5A). SdhA-CBM2 or SdhA-CBM2A exhibited a higher affinity for ASH/RhoGAP than Rab5a
271 (Q79L). SdhA-CBM2A ($EC_{50} \sim 8.1$ nM) showed approximately 12-fold higher binding compared
272 to the Rab5a (Q79L) ($EC_{50} \sim 97.3$ nM), arguing that SdhA may act by competing with known
273 binding partners of OCRL (Fig. 5A). We further examined potential competition between SdhA
274 fragments and Rab5a (Q79L) for OCRL binding. The ASH or ASH/RhoGAP domains were
275 immobilized and challenged with 22 nM Rab5 in the presence of increasing amounts of SdhA-
276 CBM2 or SdhA-CBM2A. Interestingly, the lower affinity SdhA-CBM2 fragment disrupted
277 Rab5a (Q79L) binding to either the ASH or ASH/RhoGAP domains in a dose-dependent manner
278 (Fig. 5B,C). Of note, the smaller fragment, SdhA-CBM2A, did not affect Rab5a (Q79L) binding
279 to OCRL even though it has a higher apparent binding affinity for OCRL than SdhA-CBM2 (Fig.
280 2C). This is consistent with SdhA and Rab5 binding nonoverlapping sites on OCRL, with the
281 larger CBM2 fragment blocking binding of Rab5 due to steric effects. As would be expected
282 with the higher affinity interactions with SdhA, when either 22 nM of the CBM2 or 7.4 nM of
283 CBM2A fragments were challenged for ASH or ASH/RhoGAP binding in the presence of
284 increasing amounts of Rab5a (Q79L), the Rab protein had no effect on SdhA fragment binding to
285 the OCRL domains (Fig. 5D,E). Thus, under the conditions tested here, the SdhA CBM2
286 fragment outcompetes Rab5 for binding to OCRL. This is consistent with our assays showing
287 more efficient SdhA:OCRL binding than we observed for Rab5:OCRL interaction (Fig. 5A).

288 We next analyzed whether SdhA directly affects the catalytic activity of OCRL as a
289 consequence of binding the ASH domain, which is proximal to the 5-phosphatase domain of
290 OCRL (Fig.1A). To this end, the 5-phosphatase activity was assayed using purified OCRL
291 incubated with PI(4,5)P₂-containing liposomes. The 5-phosphatase activity of OCRL is

292 inherently weak in published assays in the absence of a source of stimulation, making inhibitory
293 effects difficult to detect (Billcliff et al., 2015). It has been shown that the activity is stimulated
294 by formation of tripartite complex with Ses1 and Pacsin2 (Billcliff et al., 2015), so we used these
295 components to test if SdhA interferes with the 5-phosphatase activity. Consistent with previous
296 results, the 5-phosphatase activity was dramatically stimulated in the presence of both Ses1 and
297 Pacsin2. Addition of SdhA-CBM2 in the presence of this complete reaction mix, however,
298 showed no significant depression of the stimulated activity (Fig. 5F). SdhA-CBM2 was clearly
299 competent to bind OCRL using these assay conditions, as His-OCRL efficiently pulled down
300 GST-SdhA-CBM2, but not GST alone (Fig. 5G). These results indicate that SdhA likely hijacks
301 OCRL, interrupting binding of cellular partners without disrupting its phosphatase activity.

302

303 **Cellular depletion of OCRL enhances the integrity of LCVs harboring the *sdhA* mutant**

304 To assess the role of OCRL in modulating LCV integrity, OCRL was efficiently RNAi-
305 depleted in COS-7 cells (Fig. 6A). The OCRL-depleted cells were next challenged for either 4 or
306 8 hrs with $\Delta sdhA$ or WT strains and the relative levels of disrupted LCVs was determined by
307 immunostaining (Experimental Procedures). Cells depleted of OCRL showed a significant
308 enhancement in the integrity of vacuoles harboring the $\Delta sdhA$ strain at both time points,
309 indicating that the absence of OCRL stabilized the *sdhA*-containing vacuole (Fig. 6B). OCRL
310 knockdown also resulted in enhanced intracellular growth of $\Delta sdhA$ as well as WT in COS-7
311 cells (Fig. 6C).

312

313 **OCRL accumulates on the disrupted vacuole of *sdhA* mutants**

314 Previous work has shown that OCRL localizes to LCVs in *D. discoideum* and RAW264.7
315 macrophages (Weber et al., 2009). To determine if SdhA is involved in the localization of OCRL
316 on LCVs, we challenged U937 macrophages for 3hrs with a $\Delta sdhA$ strain harboring either a
317 plasmid overproducing SdhA or an empty vector control. After homogenization of infected
318 macrophages, the localization of SdhA and endogenous OCRL on LCVs in post-nuclear
319 supernatants was determined by immunofluorescence microscopy. Approximately 90% of the
320 LCVs stained positively for OCRL regardless of the presence of SdhA (Fig. 6D,E). The pattern
321 of OCRL localization on the LCVs, however, could clearly be differentiated between the two
322 strains. In the presence of SdhA, OCRL formed punctate structures associated with LCVs that
323 appeared to be enveloped by SdhA. In contrast, there was dense circumferential accumulation of
324 OCRL about the LCV in absence of *sdhA* (Fig. 6D) (more images in Fig. S4). Based on image
325 analysis, the median fluorescence intensity of OCRL accumulation about vacuoles was
326 approximately 1.4 times greater in the absence of SdhA than in its presence, with a broad
327 distribution of intensities observed for the mutant, pointing toward two populations of LCVs
328 ($P < 0.0001$; Mann-Whitney U-test; Fig. 6F). To investigate this distribution further and test if
329 vacuole disruption was related to accumulated OCRL, we quantified OCRL on intact or
330 disrupted LCVs (Fig. 6G). There was a significant correlation between OCRL intensity and
331 vacuole disruption. For the strain lacking SdhA, the median OCRL fluorescence intensity of
332 disrupted LCVs was 1.6-fold greater compared to those with intact LCVs ($P < 0.0001$; Mann-
333 Whitney U-test). The OCRL intensity of intact LCVs containing the empty vector strain was
334 significantly higher than the OCRL intensity of LCVs containing the pSdhA strains, indicating
335 OCRL accumulation occurs before vacuole disruption and then continues to accumulate (Fig.

336 6G). Therefore, SdhA interferes with the accumulation of OCRL on LCVs and is associated with
337 vacuole disruption.

338

339 **SdhA inhibits the accumulation of OCRL-dependent endosomal traffic to LCVs**

340 The localization of several well-characterized host proteins associated with OCRL-
341 controlled endosomal traffic was assessed by immunofluorescence microscopy of LCVs from
342 postnuclear supernatants of U937 cells (Vicinanza et al., 2011). We quantified the number of
343 LCVs positive for endosomal EEA1, retrograde cargo trafficking cation-independent mannose 6-
344 phosphate receptor (CIMPR), and TfR, linked to recycling cargo (Fig. 7A). For EEA1 and
345 CIMPR, there was a significant increase in LCV association for each marker after infection with
346 a Δ *sdhA* strain for 3hrs when compared to WT. The increase was particularly striking with
347 EEA1, supporting our previous analysis of the behavior of Δ *sdhA* strains with murine bone
348 marrow-derived macrophages (Anand et al., 2020) (Fig. 7A).

349 To assess whether enhanced accumulation of EEA1 on LCVs harboring *sdhA* mutants is
350 dependent on OCRL, OCRL was depleted by siRNA prior to infection. In comparison to the
351 control with scrambled siRNA, EEA1 positive LCVs harboring the Δ *sdhA* strain decreased to a
352 level that was indistinguishable from WT (Fig. 7B). This indicates that aberrant trafficking of
353 EEA1 to LCVs harboring the Δ *sdhA* mutant appeared largely dependent on OCRL function,
354 consistent with SdhA controlling OCRL function for the purpose of blockading early endosomal
355 vesicles.

356

357

358

359 Discussion

360 Mammalian OCRL protein and its *Dictyostelium discoideum* homologue Dd5P4 localize
361 to the *Legionella*-containing vacuole (LCV), limiting intracellular replication of *L. pneumophila*
362 (Weber et al., 2009, Finselet et al., 2013). In our study, we argue that OCRL promotes events
363 that disrupt LCV integrity, with SdhA protein being a key player in preventing OCRL restriction
364 of pathogen growth. As SdhA is one of the few Icm/Dot translocated substrates required for
365 survival in primary macrophages, the interface of SdhA with this host inositol polyphosphate 5-
366 phosphatase is likely to be a critical step in controlling the balance between host innate
367 restriction and proliferation of the pathogen. The OCRL phosphatase activity is known to control
368 a number of membrane trafficking steps. The results documented here argue that SdhA blocks an
369 OCRL-regulated step in the movement of vesicles from an endosomal compartment, resulting in
370 disruption of the LCV membrane. Presumably the blockade occurs by SdhA hijacking of OCRL.

371 We have found that RNAi depletion of OCRL in cells challenged with the *sdhA* mutant
372 significantly increases the number of intact LCVs, consistent with a role for OCRL in driving
373 vacuole membrane disruption. Similarly, OCRL depletion in COS-7 cells stimulates intracellular
374 replication of the *L. pneumophila* $\Delta sdhA$ (Fig. 6B,C). Immunofluorescence detection of OCRL
375 interaction with the LCV indicates that there are likely two modes of OCRL interface with the
376 vacuole (Fig. 6). On encounter with vacuoles harboring WT *L. pneumophila*, OCRL-staining
377 compartments target to SdhA-rich regions. In contrast, loss of SdhA function enhances OCRL
378 circumferential recruitment about the LCV, and this recruitment appears particularly robust in
379 vacuoles undergoing disruption (Fig. 6G). Taken together, these results argue that the LCV
380 surrounding the *sdhA* mutant vacuole merges with OCRL-containing compartments, resulting in

381 eventual vacuole disruption. In cells harboring the WT strain, vacuole integrity is maintained as a
382 consequence of diversion of these compartments by SdhA.

383 In previous work, we presented evidence that SdhA likely acts by preventing access of
384 endosome-derived compartments to the LCV (Anand et al., 2020). This model was based on
385 RNAi screens demonstrating that disruption of $\Delta sdhA$ mutant-containing vacuoles can be
386 reversed by depletion of endocytic Rab GTPases. A primary consequence of SdhA loss was
387 shown to be the accumulation of early endosomal protein EEA1 on the defective vacuole in
388 primary macrophages, dependent on the function of Rab5 and Rab11 (Anand et al., 2020). As a
389 number of GTPases involved in endosome dynamics, such as Rab5 and Rab8 are known
390 interacting partners of OCRL (Grant and Donaldson, 2009), we asked whether disrupting OCRL
391 function similarly could block this aberrant EEA1 accumulation. The depletion of OCRL
392 dramatically decreased EEA1 association with the $\Delta sdhA$ vacuole (Fig. 7B).

393 Based on these results, we hypothesize that in the absence of SdhA, OCRL and Rab
394 GTPase interactions recruit endosomal compartments to the $\Delta sdhA$ vacuole and disrupt the
395 pathogen niche. In the vacuole harboring WT bacteria, SdhA can bind OCRL and interfere with
396 Rab binding to the phosphatase, preventing OCRL-containing compartments from directly
397 targeting the vacuolar membrane. The fact that SdhA binds to the ASH domain of OCRL (Fig. 2)
398 and sterically blocks Rab protein interaction with OCRL may be significant in this regard. OCRL
399 mutants defective in Rab binding have been shown to result in aberrant OCRL targeting, and
400 depletions of Rab1 or Rab6 show similar defects (Hyvola et al. 2005). Therefore, association of
401 OCRL-containing vesicles with SdhA and consequent disruption of Rab protein binding could
402 prevent Rab effectors from promoting efficient docking of either OCRL or its associated
403 endosomes with the LCV surface.

404 The relatively small CBM2A region in the C-terminal of SdhA (aa1029-80), predicted to
405 form one of several coiled-coil structures throughout the protein, is sufficient to bind the OCRL
406 ASH domain (Fig. 2). This region in SdhA is functionally important, as overproduction of a
407 variant of the protein that precisely deletes this region fails to complement the $\Delta sdhA$ mutation
408 (Fig. 3 and Fig. S1). Consistent with the defect being tightly associated with loss of OCRL
409 control, OCRL is profoundly altered in transfectants overexpressing SdhA, resulting in giant
410 OCRL-encompassed vacuoles that surround SdhA-rich regions (Fig. 4). Loss of OCRL function
411 has been documented to generate large vacuoles harboring endosomal components, thought to
412 result from blockading of endosomal traffic to the Golgi (Vicinanza et al., 2011, Choudhury et al.,
413 2005, Kadhi et al., 2011). As a consequence, disrupted OCRL causes accumulation of PI(4,5)P₂
414 in endosomal compartments and disruption of transferrin receptor (TfR) recycling (Vicinanza et
415 al., 2011, Choudhury et al., 2005, Kadhi et al., 2011). Overexpression of SdhA exactly
416 phenocopies the functional loss of OCRL, as we have demonstrated that SdhA transfectants
417 cause both mislocalization of PI(4,5)P₂ and dysfunctional TfR recycling (Fig. 4).

418 It seems counterintuitive that OCRL function should be associated with LCV disruption.
419 The LCV is rich in PI4P, so it might be thought that OCRL would play a collaborative role in
420 LCV biogenesis, as its inositol polyphosphate 5-phosphatase activity can generate PI4P, which in
421 turn anchors a wide swath of Icm/Dot effector proteins to the LCV cytoplasmic surface (Weber
422 et al., 2006; (Hsu et al., 2012)). *L. pneumophila* has a number of well-characterized translocated
423 inositol phosphate kinase and phosphatases capable of modulating PI4P dynamics, consistent
424 with maintaining PI4P homeostasis in the LCV (Dong et al., 2016; Hsu et al., 2012; Toulabi et
425 al., 2013). It seems likely that OCRL plays a surprising negative role by stimulating the
426 biogenesis, recruitment or docking of forbidden membrane compartments that act to destabilize

427 the LCV rather than directly modifying the LCV. Alternatively, the presence of OCRL on the
428 vacuolar membrane could disrupt the PI4P homeostatic balance provided by *Legionella* Icm/Dot
429 effectors, resulting in overload of this lipid and hypersensitivity to phospholipases.

430 As we have previously argued, SdhA belongs to a larger class of pathogen proteins called
431 vacuole guards that act to prevent intravacuolar microbial pathogens from being attacked by
432 disruptive membrane components largely derived from endosomes and recycling compartments
433 (Anand et al., 2020). SdhA fits in well with this class of proteins, as blocking vesicular transit of
434 these compartments to the LCV increases vacuole stability (Anand et al., 2020). By binding
435 OCRL, SdhA may play a role in modulating self-nonsel self recognition by the LCV. Forbidden
436 compartments harboring OCRL may have membrane compositions rich in PI4P that are similar
437 to that of the LCV. This, in turn, could direct targeting and fusion of these disruptive
438 compartments with the LCV. SdhA acts to “guard” the pathogen-containing vacuole by binding
439 and diverting OCRL, preventing either direct interaction with disruptive compartments or
440 blocking association of OCRL with the LCV.

441 Although the newly described SdhA biochemical activity has not been observed
442 previously, the connection of OCRL to the endocytic and recycling compartments increases
443 documented parallels between SdhA and the *Salmonella* SifA protein (Beuzon et al., 2000;
444 McGourty et al., 2012). Both SifA and SdhA are required to maintain the integrity of their
445 respective vacuoles, with failure to prevent host cell-mediated disruption resulting in release of
446 bacteria into the cytosol and activation of a Caspase 4/11-Gasdermin D-dependent pyroptotic
447 response in phagocytes (Aachoui et al., 2013; Casson et al., 2015; Pilla et al., 2014; Shi et al.,
448 2015). An intimate connection between maintaining vacuole integrity and preserving appropriate
449 lipid content of the vacuolar membrane has long been suspected in both cases, primarily based

450 on suppressor mutation analysis (Creasey and Isberg, 2012; Kolodziejek et al., 2019). Finally,
451 our work argues that SdhA regulates the host cell endocytic/recycling pathways, reminiscent of
452 the demonstrated role of SifA in hijacking retrograde cellular transit and controlling egress of
453 CIMPR (Dumont et al., 2010; McEwan et al., 2015; McGourty et al., 2012), as observed here
454 (Figs. 4E, 7A). This argues that components of the endosomal pathway act as important
455 disruptive forces that can block pathogen growth without directly targeting the organism into a
456 lysosomal compartment. The details of the nature of these disruptive forces, and the
457 phospholipid composition that results in destabilization of these compartments, remain to be
458 determined.

459

460 **Acknowledgements.** This work was supported by HHMI and NIAID grants R01
461 AI113211 and R01 AI146245 to RRI. We thank Ila Anand for scientific discussions throughout
462 the course of this work, and Kristen Davis, Wenwen Huo, Erion Lipo, and Seongok Kim for
463 review of the manuscript. We thank Dr. Pietro De Camilli for providing OCRL antibody and
464 GFP-OCRL construct; Dr. Matthias Machner for Rab5a (Q79L) construct. We also thank Drs.
465 Elizabeth Draganova and Ellen White for patient help setting up the lipid extrusion assays and
466 with Baculovirus expression.

467 **Figure legends**

468 **Figure 1. SdhA directly interacts with OCRL, but independently of F&H motif.**

469 (A) Conserved motifs of SdhA and OCRL, and maps of GST- or His- fusions. Motifs identified
470 by Eukaryotic Linear Motif resource (www.ELM.eu.org). PH: pleckstrin homology; 5 PPase: 5
471 inositol polyphosphate phosphatase; ASH: ASPM-SPD2-Hydin; RhoGAP: Rho GTPase
472 activating protein. (B) TOP: HA-mcherry or HA-mcherry-SdhA overexpressed in HEK cells
473 were immunoprecipitated (IP) with anti-HA. AP(B): AP complex β subunit. The amount of input
474 (0.2% lysates) and IP (20%) is shown. BOTTOM: Densitometry of co-immunoprecipitation.
475 Average of two sets of independent experiments. (C) Purified GST fusions were used in
476 pulldowns (GST PD) as described (Experimental Details). The amount of input (1% of total
477 lysate) and resulting precipitate (20% of total) is shown. RIGHT PANEL: Ratio of the pull-down
478 by densitometry. (D) GST-pulldowns as in (C) using SdhA-CBM2 mutations in F&H motif
479 (F1195A H1199A; FH*) or clathrin box motif (L1177A L1178A; LL*). (E) 96-well plates
480 coated with ASH/RhoGAP domain challenged with GST-tagged SdhA peptides (Experimental
481 Details). SdhA binding to OCRL detected using anti-GST antibodies and chromogenic substrate
482 (mean \pm SD, n=3). (F) Competition test of SdhA-CBM2 vs F&H motif peptide of Ses1 and
483 OCRL binding-defective point mutation (Swan et al., 2010).

484

485 **Figure 2. Mapping of the interacting regions of SdhA and OCRL using solid phase binding**
486 **assays.**

487 (A) Constructs designed based on the coiled-coils prediction by ncoils (Lupas et al., 1991). (B)
488 SdhA-CBM2A binds to ASH-RhoGAP domain. Plate coated with ASH/RhoGAP was challenged
489 with indicated SdhA constructs. EC₅₀ was calculated as described (Experimental Details). (C)

490 High affinity binding of CBM2A to ASH-RhoGAP. Protocol as in 2(B). (D) SdhA-CBM2
491 associates with ASH domain specifically. Plate coated with SdhA-CBM2 was challenged with
492 His- tagged OCRL domains. Binding detected by anti-His antibodies. His-G α i was used as a
493 negative control.

494

495 **Figure 3. The OCRL binding region of SdhA is required for maintaining LCV integrity**
496 **and intracellular growth in macrophages.**

497 BMDMs from the A/J mouse were challenged at MOI = 1 with *L. pneumophila* WT or Δ *sdhA*
498 harboring SdhA variants. (A) SdhA localization on LCV was determined by
499 immunofluorescence using antibodies against SdhA at 3hpi (Scale bar, 2 μ m). See also Fig S1.
500 (B) SdhA mutants do not rescue Δ *sdhA* vacuole disruption. Macrophages were challenged for
501 8hr, fixed, and stained for bacteria before and after permeabilization, and internalized bacteria in
502 absence of permeabilization were quantified relative to total infected population (mean \pm SD,
503 n=3). (C) Growth of *L. pneumophila* strains in macrophages, determined by the number of
504 bacteria per vacuole 16h post uptake (mean \pm SD, n=3).

505

506 **Figure 4. SdhA overexpression phenocopies loss of OCRL function.**

507 (A) Representative micrographs of fixed COS-7 cells co-expressing mCherry-SdhA (red) and
508 GFP- OCRL (green). DNA labeled by Hoechst stain (blue). (Scale bar, 10 μ m). See also Fig. S2.
509 (B) mCherry-SdhA localizes to endocytic vesicles resulting in enlarged compartments. COS-7
510 cells expressing mCherry-SdhA (right panel) or mCherry (CTR, left panel) were either
511 immunostained for EEA1 (green) or transfected with GFP-Rab7 or YFP-Rab11 (green). DNA
512 labeled with Hoechst (blue). (C) COS-7 cells co-expressing mCherry-SdhA and GFP-PLC δ -PH.

513 Additional images in Fig. S3. SdhA impairs endocytosis (D) and recycling of Tf (E). COS-7 cells
514 were transfected with indicated expression vectors, mCherry or mCherry-SdhA. At 24 hr after
515 transfection, cells were incubated with Alexa 488-Tf. (D) Uptake of Tf was measured as mean
516 fluorescence intensities at 15 min. (E) For Tf recycling, the cells were loaded with Tf for 1 hr at
517 37°C (Load) and chased in complete medium for 40 and 60 min (Chase). Arrows indicate SdhA-
518 transfected cells. The fluorescence intensity remaining in cell was quantified and expressed as
519 percentages of the loaded Tf. Data are mean values \pm SD (n=25 in triplicate) (*P<0.01;
520 **P<0.05; ***P<0.001). Scale bars = 10 μ m.

521

522 **Figure 5. SdhA interrupts Rab5 binding.**

523 (A) High affinity binding of SdhA variants to OCRL. ASH-RhoGAP was immobilized and
524 challenged with indicated GST-tagged proteins. EC₅₀ were calculated and expressed as nM
525 (Experimental Details). (B) Competitive binding of Rab5 and SdhA to ASH domain.
526 Immobilized ASH domain was challenged with 22nM Rab5a (Q79L) in combination with
527 increasing amounts of GST-fused SdhA constructs. (C) Same as in (B), except ASH/RhoGAP
528 domain was immobilized. (D) SdhA binding to ASH domain of OCRL was not affected by
529 challenge with Rab5a. Same as in (B), but constant amounts of SdhA (CBM2=22nM,
530 CBM2A=7.4nM) and increasing amounts of Rab5a (Q79L). (E) Same as in (D), but
531 ASH/RhoGAP domain was immobilized. (F) SdhA-CBM2 does not affect the Ses1- and
532 Pacsin2-stimulated 5-phosphatase activity of OCRL. Phosphatase activity was measured as
533 described (Experimental Details). His- OCRL (50 nM) was incubated with indicated proteins and
534 with 200 μ M of PI(4,5)P₂-containing liposomes. Data expressed as percentage of 5-phosphatase
535 activity compared to incubation of OCRL with liposomes. Data represent triplicate assays \pm SE

536 (standard error). (*P<0.01; **P<0.05; ***P<0.001) (G) SdhA-CBM2 binding to OCRL during 5-
537 phosphatase assay in (F) demonstrated by pulldown assay. His-OCRL and SdhA-CBM2 were
538 collected with Ni²⁺ resin and analyzed by Coomassie staining. The amount input (10%), unbound
539 FT (flowthrough, 20%) and bound PD (pulldown 50%) are displayed.

540

541 **Figure 6. OCRL is linked to vacuole disruption of *L. pneumophila sdhA* mutants.**

542 (A) COS-7 cells treated with OCRL-targeting (siOCRL) or non-targeting control siRNA (siCon)
543 for 72hrs were gel fractionated and immunoprobed with antibodies directed against noted
544 proteins. (B) COS-7 cells were depleted by siRNA (3 days) and then challenged at MOI =5 with
545 noted *L. pneumophila* strains. Cells were fixed and stained for bacteria before and after
546 permeabilization, as in Fig. 4B. Data are mean values ± SD (n=3) (**P<0.05). (C) *L.*

547 *pneumophila lux*⁺ strains were incubated with COS-7 cells at MOI = 20 and bacterial yield was
548 measured 48 hrs post infection by relative luminescence (RLU). The replication-deficient *dotA*
549 null mutant Lp03 was used as a negative control. Data are mean values ± SD (n=3). (D)

550 Confocal image showing a section of vacuoles isolated from infected U937 cells (MOI = 10, 3h)
551 with $\Delta sdhA$ mutant harboring pSdhA or pJB vector. The presence of OCRL and SdhA on LCVs
552 was assessed by immunofluorescence using antibodies directed against OCRL, SdhA and *L.*

553 *pneumophila*. (Scale bar, 4 μm). See also Fig S4. (E) Quantification of OCRL positive LCVs

554 containing $\Delta sdhA$ mutants with pSdhA or pJB vector at 3hpi. Data are mean values ± SD (n=3)

555 (>85 LCVs each replicate). (F) Plot of OCRL intensity associated with LCV (n>70), with

556 medians displayed. (G) Plot comparing the OCRL intensity on LCVs harboring pSdhA

557 compared to strain harboring empty pJB vector, divided into impermeable and permeable LCVs

558 (n>70). (****P<0.0001, Mann-Whitney U-test)

559

560 **Figure 7. OCRL-dependent accumulation of endosomal compartments on vacuole**

561 **surrounding $\Delta sdhA$ mutant.**

562 (A) U937 macrophages were challenged for 3 hr with *L. pneumophila* wild type and $\Delta sdhA$
563 (MOI = 10). The presence of endosomal EEA1, retrograde trafficking cargo CIMPR, and
564 recycling endosomal TfR on LCVs was evaluated by immunofluorescence microscopy in
565 postnuclear supernatants of infected cells (Experimental Details). Data are mean values \pm SD of
566 triplicate samples. Scale bar represents 4 μ m. (B) LEFT PANEL: Effect of siOCRL on protein
567 expression in U937 cells. GAPDH was used as a loading control. Gel fractionated samples were
568 immunoprobed with indicated antibodies. RIGHT PANEL: The presence of EEA1 on LCVs was
569 quantified from the infected U937 cell lysates as in panel (A). (* $P < 0.01$; ** $P < 0.05$)

570

571 **Figure S1. Characterization of SdhA mutants.**

572 (A) Growth of noted strains in AYE broth. Strains with $\Delta sdhA$ allele have noted genes inserted
573 into pJB908 (Vector). (B) Western blot analysis of expression levels of SdhA variants. Isocitrate
574 dehydrogenase (ICDH) was used for loading control. (C) The presence of SdhA variants on LCV
575 surface was assessed by fluorescence microscopy as in Fig. 3A. SdhA is undetectable in WT
576 strain and must be overproduced on pJB908 to identify by immunofluorescence microscopy.
577 Each of the $\Delta sdhA$ strains harbor pJB908 with noted chromosomal fragments. Data represents
578 means and SDs of triplicates.

579

580 **Figure S2. Ectopically expressed SdhA associates with OCRL positive compartments.**

581 Representative micrographs of fixed COS-7 cells coexpressing mCherry-SdhA (red) and GFP-
582 tagged OCRL. DNA was labeled by Hoechst stains (blue). Cells were treated with nocodazole
583 (NOCO) to release aggregation of the compartments. (Scale bar, 10 μ m)

584

585 **Figure S3. COS-7 cells coexpressing mCherry-SdhA and GFP-PLC δ -PH demonstrate**
586 **rearrangement and internalization of PI(4,5)P₂.**

587 Scale bar represents 20 μ m.

588

589 **Figure S4. OCRL localization about the LCV surface.**

590 Linked to Fig. 6D. Confocal images of vacuoles isolated from infected U937 cells (MOI =10, 3h)
591 with Δ *sdhA* mutant harboring pSdhA or pJB vector. The presence of OCRL and SdhA on LCVs
592 was assessed by immunofluorescence using antibodies against OCRL, SdhA and *L.*
593 *pneumophila*. (Scale bar, 4 μ m)

594

595

596 **STAR METHODS**

597 **KEY RESOURCES TABLE**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|--|--------------------------------|------------------|
| Antibodies | | |
| Mouse monoclonal anti-HA | Santa Cruz | Cat# SC7392 |
| Rabbit polyclonal anti-OCRL | Sigma | Cat# O7640 |
| Goat polyclonal anti-AP2B | Santa Cruz | Cat# SC6425 |
| Mouse monoclonal anti-OCRL | Pietro De Camilli | N/A |
| Rabbit polyclonal anti-GFP | Life Technologies | Cat# A11122 |
| Mouse monoclonal anti-GST | Santa Cruz | Cat# SC138 |
| Mouse monoclonal anti-polyHis | Sigma | Cat# H1029 |
| Rabbit polyclonal anti-Rab5A | Santa Cruz | Cat# SC-309 |
| Mouse monoclonal anti-EEA1 | BD Transduction | Cat# 610456 |
| Mouse monoclonal anti-GAPDH | Santa Cruz | Cat# SC32233 |
| Mouse monoclonal anti-CIMPR | Novusbio | Cat# NB300-514 |
| Mouse monoclonal anti-TfR | Abcam | Cat# AB9179 |
| Mouse monoclonal anti- β -Tubulin | Sigma | Cat# T4026 |
| HRP-conjugated rabbit anti-goat | Life Technologies | Cat# 611620 |
| HRP-conjugated goat anti-mouse | Life Technologies | Cat# 626520 |
| HRP-conjugated goat anti-rabbit | Life Technologies | Cat# 65-6120 |
| Alexa488-conjugated donkey anti-rabbit | Jackson ImmunoResearch | Cat# 711-545-152 |
| Alexa488-conjugated donkey anti-mouse | Jackson ImmunoResearch | Cat# 715-545-150 |
| Alexa 594-conjugated donkey anti-rat | Jackson ImmunoResearch | Cat# 712-585-153 |
| Alexa594-conjugated donkey anti-rabbit | Jackson ImmunoResearch | Cat# 711-585-152 |
| Dylight 405-conjugated donkey anti-Rat | Jackson ImmunoResearch | Cat# 712-475-153 |
| Rabbit polyclonal anti-SdhA | (Laguna et al., 2006) | N/A |
| Rabbit polyclonal anti-ICDH | (Dumenil et al., 2004) | N/A |
| Rat monoclonal anti-Legionella | (Isaac et al., 2015) | N/A |
| Rabbit polyclonal anti-Legionella | (Isaac et al., 2015) | N/A |
| Bacterial Strains | | |
| <i>L. pneumophila</i> Lp02 | (Berger and Isberg, 1993) | N/A |
| <i>L. pneumophila</i> Lp02 Δ sdhA | (Zhu et al., 2011) | N/A |
| <i>L. pneumophila</i> Lp03 (Lp02 dotA03) | (Berger and Isberg, 1993) | N/A |
| <i>L. pneumophila</i> Lp02 lux+ (P _{ahpC} ::lux) | (Ensminger et al., 2012) | N/A |
| <i>L. pneumophila</i> Lp02 Δ sdhA lux+ (kan ^R P _{ahpC} ::lux) | (Anand et al., 2020) | N/A |
| Chemicals, Peptides, and Recombinant Proteins | | |
| Western Lightning Plus-ECL | PerkinElmer | NEL105001EA |
| Nocodazole | Sigma | M1404 |
| DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) | Avanti Polar Lipids | Cat# 850375 |
| DOPS (1,2-dioleoyl-sn-glycero-3-phospho-l-serine) | Avanti Polar Lipids | Cat# 840035 |
| Brain PI(4,5)P ₂ | Avanti Polar Lipids | Cat# 840046 |
| Malachite green phosphate assay kit | Sigma | Cat# MAK307 |
| Peptide Ses1-F&H 13mer (PFARLHECYGQEI) | Tufts University Core Facility | N/A |

| | | |
|---|--------------------------------|-----------------------|
| Peptide Ses1-FA (PAARLHECYGQEI) | Tufts University Core Facility | N/A |
| Protease inhibitor cocktail | Roche | Cat# 11873580001 |
| Lipofectamine 2000 | Invitrogen | Cat# 11668030 |
| Lipofectamine RNAiMAX | Invitrogen | Cat# 13778075 |
| Alexa-Fluor-488-Tf | Invitrogen | Cat# T13342 |
| Amaya cell line nucleofector kit | Lonza | Cat# VCA-1004 |
| TMB substrate kit | Pierce | Cat# 34021 |
| Anti-HA affinity beads | Sigma | Cat# E6779 |
| Experimental Models: Cell Lines | | |
| HEK 293T | ATCC | CRL-11268 |
| Mouse bone marrow-derived macrophages | This study | N/A |
| COS-7 | ATCC | CRL-1651 |
| U937 | ATCC | CRL-1593.2 |
| Experimental Models: Organisms/Strains | | |
| Mouse: A/J | The Jackson laboratory | Cat# 000646 |
| Oligonucleotides | | |
| See Table S2 for the list of oligonucleotides | IDT | N/A |
| Non-targeting siRNA pools | Dharmacon | Cat# D-001810-10-05 |
| siRNA SMARTpool for human OCRL | Dharmacon | Cat# L-010026-00-0005 |
| Recombinant DNA | | |
| pHA-mcherry-SdhA | This study | N/A |
| pGEX-6P-1-SdhA-CBM1 (350-402aa) | This study | N/A |
| pGEX-6P-1-SdhA-CBM2 (1029-1260aa) | This study | N/A |
| pGEX-6P-1-SdhA-CBM2 FH* (F1195A H1199A) | This study | N/A |
| pGEX-6P-1-SdhA-CBM2 LL* (L1177A L1178A) | This study | N/A |
| pGEX-6P-1-SdhA-CBM2 LL* (L1177A L1178A) | This study | N/A |
| pGEX-6P-1-SdhA-CBM2 ΔFH (Δ1193-1209aa) | This study | N/A |
| pGEX-6P-1-SdhA-CBM2A (1029-1080aa) | This study | N/A |
| pGEX-6P-1-SdhA-CBM2B (1075-1110aa) | This study | N/A |
| pGEX-6P-1-SdhA-CBM2C (1140-1185aa) | This study | N/A |
| pGEX-6P-1-SdhA-CBM2D (1225-1260aa) | This study | N/A |
| pGFP-OCRL | (Mao et al., 2009) | N/A |
| pQE80L-ASH/RhoGAP of OCRL (536aa-901aa) | This study | N/A |
| pQE80L-ASH of OCRL (536aa-678aa) | This study | N/A |
| pGEX6P-1-RGS-6xHis-RhoGAP of OCRL (678-901aa) | This study | N/A |
| pGEX-Rab5a (Q79L) | (Gaspar and Machner, 2014) | N/A |
| pJB908 | (Sexton et al., 2004) | N/A |
| pJB908- <i>sdhA</i> | (Zhu et al., 2011) | N/A |
| pJB908-3xflag- <i>sdhA</i> | This study | N/A |
| pJB908-3xflag- <i>sdhA</i> Δ1029-1260aa (ΔCBM2) | This study | N/A |
| pJB908-3xflag- <i>sdhA</i> Δ1029-1260aa (ΔCBM2) | This study | N/A |
| pGFP-PLCδ-PH | (Sarantis et al., 2012) | N/A |
| pGFP-Rab7 | Sina Mohammadi | N/A |
| pHA-mYFP-Rab11 | (Mohammadi and Isberg, 2013), | N/A |

| | | |
|---------------------------------------|--------------------------|---|
| pGEX-4T-2-192-249aa of IPIP27A (Ses1) | (Noakes et al., 2011) | N/A |
| pGEX-4T-2-Pacsin 2 | (Billcliff et al., 2016) | N/A |
| pFastBac-6xHis-OCRL | This study | N/A |
| Software and Algorithms | | |
| Prism | GraphPad | graphpad.com/scientific-software/prism/ |
| ImageJ | NIH ImageJ | imagej.nih.gov/ij/ |
| Eukaryotic linear motif resource | ELM | elm.eu.org |
| ncoils | Bio.tools | bio.tools/ncoils |
| Volocity | PerkinElmer | N/A |

598

599 **RESOURCE AVAILABILITY**

600 **Lead Contact**

601 Further information and requests for resources and reagents should be directed to the Lead

602 Contact, Ralph R. Isberg (ralph.isberg@tufts.edu).

603 **Materials Availability**

604 The materials generated in this study are available upon request.

605 **Data and Code Availability**

606 The published article includes all data generated or analyzed during this study.

607

608 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

609 **Cell culture**

610 Bone marrow-derived macrophages (BMDMs) from A/J mice were isolated and cultured
611 as previously described (Swanson and Isberg, 1995). COS-7 cells and HEK 293T cells were
612 cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% heat-
613 inactivated FBS (Gibco). U937 cells were maintained and differentiated as described previously
614 (Losick et al., 2010).

615

616 **METHOD DETAILS**

617 **Cloning and mutagenesis**

618 The primers used for this work are listed in Table S2. His-Tagged-full length SdhA was
619 constructed in pQE80L while appropriate truncations (CBM1, CBM2, CBM2A, CBM2B,
620 CBM2C, and CBM2D) were generated in pGEX-6P-1. Mutations were generated by PCR using
621 Quikchange (Stratagene). SdhA deletions were generated by inverse PCR (Ochman et al., 1988).
622 For insect cell expression of human OCRL, the full-length cDNA with an amino-terminal 6xHis
623 tag was inserted into pFastBac vector. His-tagged ASH/RhoGAP and ASH domain of human
624 OCRL cDNA were inserted into pQE80L. The amino-terminal-6xHis fused RhoGAP domain of
625 OCRL was inserted into pGEX-6P-1 to generate GST-6His (internal tag) for purposes of
626 improving solubility of the recombinant protein. All constructs were verified by DNA
627 sequencing (Genewiz).

628 **Co-immunoprecipitation**

629 HEK 293T cells were co-transfected with GFP-OCRL and either HA-mcherry or HA-
630 mcherry-SdhA using Lipofectamine 2000 for 2 days. Lysates were made on ice for 1hr (50 mM
631 Tris-HCl, pH 7.4, 150 mM NaCl, 2% Octylglucoside, protease inhibitor cocktail) and clarified
632 by centrifugation at 16,000g for 20min at 4°C. Immune complexes from the supernatants were
633 adsorbed on anti-HA affinity beads for 2 hr at 4°C. After washing (50 mM Tris-HCl, pH 7.4, 40
634 mM NaCl, 0.2% Octylglucoside, protease inhibitor cocktail), proteins were fractionated by SDS-
635 PAGE and transferred to polyvinylidene difluoride membranes (Millipore), and probed with the
636 indicated antibodies.

637 **Pulldown experiments**

638 Pulldown experiments with purified GST or GST-SdhA truncations were performed with
639 the lysates of HEK cells transfected with GFP or GFP-OCRL after 24 hr transfection. The lysates

640 were prepared from a 10 cm dish in 1ml of pull down/lysis buffer (25 mM Hepes–KOH (pH
641 7.2), 125 mM potassium acetate, 2.5 mM magnesium acetate, 0.4% Triton X-100, and protease
642 inhibitor cocktail), followed by incubation for 3 hr at 4°C with 250 µg of GST-fusion protein
643 coupled to glutathione-agarose (Thermo Scientific). Beads were then washed four times (pull
644 down buffer containing 0.1% Triton X-100) and resuspended with SDS-PAGE sample buffer
645 followed by SDS-PAGE and Western blotting.

646 **Protein preparations**

647 6xHis-OCRL was prepared from Sf9 insect cells using a baculovirus expression system
648 (Invitrogen) according to the manufacturer’s specification. Cells were lysed (20mM Tris, pH 8,
649 150mM NaCl, 5mM MgCl₂, 5mM β-mercaptoethanol, 1% NP40, 10% glycerol, and protease
650 inhibitor) and purified by nickel affinity chromatography (GE healthcare Lifesciences). *E. coli*
651 BL21 (DE3) was used for bacterially-expressed protein, inducing overnight with 0.1 mM IPTG
652 at 18°C. GST fusion proteins were purified on glutathione superflow agarose according to the
653 manufacturer’s protocol (Thermo Scientific). The GST tag of N-terminal GST-6xHis-RhoGAP
654 domain was removed by addition of PreScission protease (GE healthcare Lifesciences) directly
655 to the glutathione beads followed by incubation overnight at 4°C to obtain His-tagged RhoGAP.
656 His-tagged proteins were purified by nickel affinity chromatography. The proteins were then
657 concentrated by ultrafiltration using Amicon filters (EMD Millipore).

658 **Solid phase binding assay**

659 96-well ELISA plates (Thermo Fisher) were coated with 1µg of recombinant proteins (20
660 mM NaHCO₃/Na₂CO₃, pH 9.4), washed four times (Tris (pH=7.4)-buffered saline (TBS),
661 0.1% Tween 20 (TBST)), and blocked in TBS + 5% BSA. Wells were then probed with GST- or
662 His-tagged proteins diluted in TBST containing 0.5% BSA for 1 hr. Wells were washed again

663 with TBST and incubated with appropriate primary antibodies and HRP-conjugated secondary
664 antibodies. Protein interaction was detected by incubating with TMB (Thermo Fisher) as a
665 chromogenic substrate. The reactions were stopped (1M HCl and 5M acetic acid in water) and
666 the resulting absorbance was measured at 405 nm in a microtiter plate spectrophotometer.
667 EC₅₀ was calculated using the GraphPad Prism 8 software for windows applying the nonlinear
668 curve fit module.

669 **Bacterial challenge of mammalian cells**

670 The analysis of intracellular replication at a single cell level and analysis of cytosolic
671 bacteria in BMDMs were performed as previously described (Creasey and Isberg, 2012). To
672 quantify SdhA localization on LCV, SdhA and *L. pneumophila* were probed with anti-SdhA and
673 anti-*Legionella*, respectively, incubated with fluorescent secondary antibodies, and 100 vacuoles
674 were counted. Isolation of vacuoles from *L. pneumophila*-infected U937 was performed as
675 described previously (Vogel et al., 1998). For intracellular growth in COS-7 cells, 2x10⁴ cells
676 were seeded in 96-well plates, challenged with *L. pneumophila lux* (MOI 20) for 1 hr, washed
677 three times with Dulbecco's modified Eagle's medium (no phenol red) supplemented with 10%
678 FBS, and luciferase production was measured at 48 hr post infection in a microtiter luminometer.

679 **Imaging**

680 Fluorescence microscopy was performed following standard procedures (Losick and
681 Isberg, 2006) and all antibodies were used according to manufacturer's procedures. Nuclei were
682 stained using Hoechst stain (Invitrogen). Cells were transfected using Lipofectamine 2000
683 (Invitrogen) for 24 hr according to the manufacturer's instructions and fixed with 4%
684 formaldehyde in PBS. For nocodazole treatment, 0.1 µg/ml of nocodazole (Sigma) was added to
685 cells for 20 hrs. Cells were imaged by either Zeiss observer Z1 or Leica Falcon SP8 microscopy.

686 Images were processed using ImageJ or Volocity software (Improvision). The fluorescence
687 intensity of OCRL covering a single LCV and transferrin in the cytoplasm was quantified using
688 ImageJ software after background correction.

689 **Transferrin uptake and recycling**

690 COS-7 cells-transfected with SdhA or with control vector were incubated in serum-free
691 medium for 1 hr and then exposed to 50 μ g/ml Alexa-Fluor-488-Tf (Invitrogen) on ice for 30
692 min. The cells were transferred to 37 °C and incubated for the times indicated. External Tf was
693 removed by washing with PBS and bound Tf was removed by an acid wash (150 mM NaCl, and
694 10 mM acetic acid, pH 3.5) followed by washes with PBS. The fluorescence intensity of
695 internalized Tf was quantified by image capturing using a Zeiss Observer Z1 microscope (63x oil
696 objective) and analysis using Image J. To measure recycling, cells were incubated first in serum-
697 free medium and subsequently in medium containing fluorescent Tf for 1 h at 37 °C to saturate
698 the receptor population. After extensive washing with HEPES-buffered DMEM, the recycling of
699 Tf was followed by incubating the cells in the presence of complete medium for 40 and 60 min,
700 at 37 °C. The cells were then acid washed before fixing.

701 **Lipid phosphatase assay**

702 To measure phosphatase activity, lipid vesicles containing PI(4,5)P₂ were generated by
703 extrusion with polycarbonate membranes with pore size of 200-nm diameter as described in
704 Billcliff *et al.* (2016). Lipids DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine), DOPS (1,2-
705 dioleoyl-sn-glycero-3-phospho-l-serine), and natural PI(4,5)P₂ were purchased from Avanti Polar
706 Lipids. His-tagged OCRL (50 nM) was incubated with indicated proteins on ice for 20 min in
707 reaction buffer (50mM Tris-HCl, pH7.4, 5mM MgCl₂). Ses1 C-terminal fragment (192-249) and
708 GST-Pacsin2 were added at 20-fold molar excess of OCRL. The phosphatase reaction was

709 started by addition of 200 μ M of PI(4,5)P₂-containing liposomes. After incubation at 37°C for 20
710 min, the reaction was stopped by the addition of malachite green solution (Sigma-Aldrich) and
711 the resulting absorbance was read at 620nm.

712 **RNA interference**

713 COS-7 cells were transfected using Lipofectamine RNAiMAX (ThermoFisher Scientific)
714 according to the manufacturer's instructions. The siRNA SMARTpool for OCRL and non-
715 targeting siRNAs were purchased from Dharmacon. For OCRL depletion in U937 cells, siRNA
716 was transfected with Amaxa cell line nucleofector kit and Nucleofector II (Lonza) according to
717 the manufacturer's protocol.

718

719 References

- 720 Aachoui, Y., Leaf, I.A., Hagar, J.A., Fontana, M.F., Campos, C.G., Zak, D.E., Tan, M.H., Cotter,
721 P.A., Vance, R.E., Aderem, A., *et al.* (2013). Caspase-11 protects against bacteria that
722 escape the vacuole. *Science* 339, 975-978.
- 723 Anand, I.S., Choi, W., and Isberg, R.R. (2020). Components of the endocytic and recycling
724 trafficking pathways interfere with the integrity of the *Legionella*-containing
725 vacuole. *Cell Microbiol* 22, e13151.
- 726 Berger, K.H., and Isberg, R.R. (1993). Two distinct defects in intracellular growth
727 complemented by a single genetic locus in *Legionella pneumophila*. *Mol Microbiol* 7,
728 7-19.
- 729 Beuzon, C.R., Meresse, S., Unsworth, K.E., Ruiz-Albert, J., Garvis, S., Waterman, S.R., Ryder,
730 T.A., Boucrot, E., and Holden, D.W. (2000). *Salmonella* maintains the integrity of its
731 intracellular vacuole through the action of SifA. *EMBO J* 19, 3235-3249.
- 732 Billcliff, P.G., Noakes, C.J., Mehta, Z.B., Yan, G., Mak, L., Woscholski, R., and Lowe, M. (2016).
733 OCRL1 engages with the F-BAR protein pacsin 2 to promote biogenesis of
734 membrane-trafficking intermediates. *Mol Biol Cell* 27, 90-107.
- 735 Casson, C.N., Yu, J., Reyes, V.M., Taschuk, F.O., Yadav, A., Copenhaver, A.M., Nguyen, H.T.,
736 Collman, R.G., and Shin, S. (2015). Human caspase-4 mediates noncanonical
737 inflammasome activation against gram-negative bacterial pathogens. *Proc Natl Acad*
738 *Sci U S A* 112, 6688-6693.
- 739 Christoforidis, S., McBride, H.M., Burgoyne, R.D., and Zerial, M. (1999). The Rab5 effector
740 EEA1 is a core component of endosome docking. *Nature* 397, 621-625.
- 741 Clemens, D.L., Lee, B.Y., and Horwitz, M.A. (2000). Deviant expression of Rab5 on
742 phagosomes containing the intracellular pathogens *Mycobacterium tuberculosis* and
743 *Legionella pneumophila* is associated with altered phagosomal fate. *Infect Immun* 68,
744 2671-2684.
- 745 Copenhaver, A.M., Casson, C.N., Nguyen, H.T., Fung, T.C., Duda, M.M., Roy, C.R., and Shin, S.
746 (2014). Alveolar macrophages and neutrophils are the primary reservoirs for
747 *Legionella pneumophila* and mediate cytosolic surveillance of type IV secretion.
748 *Infect Immun* 82, 4325-4336.
- 749 Creasey, E.A., and Isberg, R.R. (2012). The protein SdhA maintains the integrity of the
750 *Legionella*-containing vacuole. *Proc Natl Acad Sci U S A* 109, 3481-3486.
- 751 De Matteis, M.A., Staiano, L., Emma, F., and Devuyt, O. (2017). The 5-phosphatase OCRL in
752 Lowe syndrome and Dent disease 2. *Nat Rev Nephrol* 13, 455-470.
- 753 Diggins, N.L., and Webb, D.J. (2017). APPL1 is a multifunctional endosomal signaling
754 adaptor protein. *Biochem Soc Trans* 45, 771-779.
- 755 Dong, N., Niu, M., Hu, L., Yao, Q., Zhou, R., and Shao, F. (2016). Modulation of membrane
756 phosphoinositide dynamics by the phosphatidylinositol 4-kinase activity of the
757 *Legionella* LepB effector. *Nat Microbiol* 2, 16236.
- 758 Dumenil, G., Montminy, T.P., Tang, M., and Isberg, R.R. (2004). IcmR-regulated membrane
759 insertion and efflux by the *Legionella pneumophila* IcmQ protein. *J Biol Chem* 279,
760 4686-4695.
- 761 Dumont, A., Boucrot, E., Drevensek, S., Daire, V., Gorvel, J.P., Pous, C., Holden, D.W., and
762 Meresse, S. (2010). SKIP, the host target of the *Salmonella* virulence factor SifA,
763 promotes kinesin-1-dependent vacuolar membrane exchanges. *Traffic* 11, 899-911.

- 764 Ensminger, A.W., Yassin, Y., Miron, A., and Isberg, R.R. (2012). Experimental evolution of
765 *Legionella pneumophila* in mouse macrophages leads to strains with altered
766 determinants of environmental survival. *PLoS Pathog* 8, e1002731.
- 767 Erdmann, K.S., Mao, Y., McCrea, H.J., Zoncu, R., Lee, S., Paradise, S., Modregger, J.,
768 Biemesderfer, D., Toomre, D., and De Camilli, P. (2007). A role of the Lowe syndrome
769 protein OCRL in early steps of the endocytic pathway. *Dev Cell* 13, 377-390.
- 770 Faucherre, A., Desbois, P., Nagano, F., Satre, V., Lunardi, J., Gacon, G., and Dorseuil, O. (2005).
771 Lowe syndrome protein Ocr11 is translocated to membrane ruffles upon Rac GTPase
772 activation: a new perspective on Lowe syndrome pathophysiology. *Hum Mol Genet*
773 14, 1441-1448.
- 774 Faucherre, A., Desbois, P., Satre, V., Lunardi, J., Dorseuil, O., and Gacon, G. (2003). Lowe
775 syndrome protein OCRL1 interacts with Rac GTPase in the trans-Golgi network.
776 *Hum Mol Genet* 12, 2449-2456.
- 777 Gaspar, A.H., and Machner, M.P. (2014). VipD is a Rab5-activated phospholipase A1 that
778 protects *Legionella pneumophila* from endosomal fusion. *Proc Natl Acad Sci U S A*
779 111, 4560-4565.
- 780 Ge, J., Gong, Y.N., Xu, Y., and Shao, F. (2012). Preventing bacterial DNA release and absent in
781 melanoma 2 inflammasome activation by a *Legionella* effector functioning in
782 membrane trafficking. *Proc Natl Acad Sci U S A* 109, 6193-6198.
- 783 Hales, C.M., Griner, R., Hobdy-Henderson, K.C., Dorn, M.C., Hardy, D., Kumar, R., Navarre, J.,
784 Chan, E.K., Lapierre, L.A., and Goldenring, J.R. (2001). Identification and
785 characterization of a family of Rab11-interacting proteins. *J Biol Chem* 276, 39067-
786 39075.
- 787 Horwitz, M.A., and Silverstein, S.C. (1980). Legionnaires' disease bacterium (*Legionella*
788 *pneumophila*) multiples intracellularly in human monocytes. *J Clin Invest* 66, 441-
789 450.
- 790 Hsu, F., Zhu, W., Brennan, L., Tao, L., Luo, Z.Q., and Mao, Y. (2012). Structural basis for
791 substrate recognition by a unique *Legionella* phosphoinositide phosphatase. *Proc*
792 *Natl Acad Sci U S A* 109, 13567-13572.
- 793 Huang, L., Boyd, D., Amyot, W.M., Hempstead, A.D., Luo, Z.Q., O'Connor, T.J., Chen, C.,
794 Machner, M., Montminy, T., and Isberg, R.R. (2011). The E Block motif is associated
795 with *Legionella pneumophila* translocated substrates. *Cell Microbiol* 13, 227-245.
- 796 Hyvola, N., Diao, A., McKenzie, E., Skippen, A., Cockcroft, S., and Lowe, M. (2006). Membrane
797 targeting and activation of the Lowe syndrome protein OCRL1 by rab GTPases.
798 *EMBO J* 25, 3750-3761.
- 799 Isaac, D.T., Laguna, R.K., Valtz, N., and Isberg, R.R. (2015). MavN is a *Legionella pneumophila*
800 vacuole-associated protein required for efficient iron acquisition during
801 intracellular growth. *Proc Natl Acad Sci U S A* 112, E5208-5217.
- 802 Kagan, J.C., and Roy, C.R. (2002). *Legionella* phagosomes intercept vesicular traffic from
803 endoplasmic reticulum exit sites. *Nat Cell Biol* 4, 945-954.
- 804 Kolodziejek, A.M., Altura, M.A., Fan, J., Petersen, E.M., Cook, M., Brzovic, P.S., and Miller, S.I.
805 (2019). *Salmonella* Translocated Effectors Recruit OSBP1 to the Phagosome to
806 Promote Vacuolar Membrane Integrity. *Cell Rep* 27, 2147-2156 e2145.
- 807 Laguna, R.K., Creasey, E.A., Li, Z., Valtz, N., and Isberg, R.R. (2006). A *Legionella*
808 *pneumophila*-translocated substrate that is required for growth within macrophages
809 and protection from host cell death. *Proc Natl Acad Sci U S A* 103, 18745-18750.

- 810 Liu, B.C., Sarhan, J., Panda, A., Muendlein, H.I., Ilyukha, V., Coers, J., Yamamoto, M., Isberg,
811 R.R., and Poltorak, A. (2018). Constitutive Interferon Maintains GBP Expression
812 Required for Release of Bacterial Components Upstream of Pyroptosis and Anti-
813 DNA Responses. *Cell Rep* 24, 155-168 e155.
- 814 Losick, V.P., Haenssler, E., Moy, M.Y., and Isberg, R.R. (2010). LnaB: a *Legionella*
815 *pneumophila* activator of NF-kappaB. *Cell Microbiol* 12, 1083-1097.
- 816 Losick, V.P., and Isberg, R.R. (2006). NF-kappaB translocation prevents host cell death after
817 low-dose challenge by *Legionella pneumophila*. *J Exp Med* 203, 2177-2189.
- 818 Luo, Z.Q., and Isberg, R.R. (2004). Multiple substrates of the *Legionella pneumophila*
819 Dot/Icm system identified by interbacterial protein transfer. *Proc Natl Acad Sci U S*
820 *A* 101, 841-846.
- 821 Lupas, A., Van Dyke, M., and Stock, J. (1991). Predicting coiled coils from protein sequences.
822 *Science* 252, 1162-1164.
- 823 Mao, Y., Balkin, D.M., Zoncu, R., Erdmann, K.S., Tomasini, L., Hu, F., Jin, M.M., Hodsdon, M.E.,
824 and De Camilli, P. (2009). A PH domain within OCRL bridges clathrin-mediated
825 membrane trafficking to phosphoinositide metabolism. *EMBO J* 28, 1831-1842.
- 826 McCrea, H.J., Paradise, S., Tomasini, L., Addis, M., Melis, M.A., De Matteis, M.A., and De
827 Camilli, P. (2008). All known patient mutations in the ASH-RhoGAP domains of
828 OCRL affect targeting and APPL1 binding. *Biochem Biophys Res Commun* 369, 493-
829 499.
- 830 McEwan, D.G., Richter, B., Claudi, B., Wigge, C., Wild, P., Farhan, H., McGourty, K., Coxon, F.P.,
831 Franz-Wachtel, M., Perdu, B., *et al.* (2015). PLEKHM1 regulates *Salmonella*-
832 containing vacuole biogenesis and infection. *Cell Host Microbe* 17, 58-71.
- 833 McGourty, K., Thurston, T.L., Matthews, S.A., Pinaud, L., Mota, L.J., and Holden, D.W. (2012).
834 *Salmonella* inhibits retrograde trafficking of mannose-6-phosphate receptors and
835 lysosome function. *Science* 338, 963-967.
- 836 Mohammadi, S., and Isberg, R.R. (2013). Cdc42 interacts with the exocyst complex to
837 promote phagocytosis. *J Cell Biol* 200, 81-93.
- 838 Muder, R.R., Yu, V.L., and Woo, A.H. (1986). Mode of transmission of *Legionella*
839 *pneumophila*. A critical review. *Arch Intern Med* 146, 1607-1612.
- 840 Nash, T.W., Libby, D.M., and Horwitz, M.A. (1984). Interaction between the Legionnaires'
841 disease bacterium (*Legionella pneumophila*) and human alveolar macrophages.
842 Influence of antibody, lymphokines, and hydrocortisone. *J Clin Invest* 74, 771-782.
- 843 Noakes, C.J., Lee, G., and Lowe, M. (2011). The PH domain proteins IPIP27A and B link
844 OCRL1 to receptor recycling in the endocytic pathway. *Mol Biol Cell* 22, 606-623.
- 845 Pilla, D.M., Hagar, J.A., Haldar, A.K., Mason, A.K., Degrandi, D., Pfeffer, K., Ernst, R.K.,
846 Yamamoto, M., Miao, E.A., and Coers, J. (2014). Guanylate binding proteins promote
847 caspase-11-dependent pyroptosis in response to cytoplasmic LPS. *Proc Natl Acad*
848 *Sci U S A* 111, 6046-6051.
- 849 Pirruccello, M., and De Camilli, P. (2012). Inositol 5-phosphatases: insights from the Lowe
850 syndrome protein OCRL. *Trends Biochem Sci* 37, 134-143.
- 851 Rowbotham, T.J. (1980). Preliminary report on the pathogenicity of *Legionella pneumophila*
852 for freshwater and soil amoebae. *J Clin Pathol* 33, 1179-1183.
- 853 Sarantis, H., Balkin, D.M., De Camilli, P., Isberg, R.R., Brumell, J.H., and Grinstein, S. (2012).
854 *Yersinia* entry into host cells requires Rab5-dependent dephosphorylation of
855 PI(4,5)P(2) and membrane scission. *Cell Host Microbe* 11, 117-128.

- 856 Segal, G. (2013). Identification of *Legionella* effectors using bioinformatic approaches.
857 *Methods Mol Biol* 954, 595-602.
- 858 Segal, G., and Shuman, H.A. (1999). *Legionella pneumophila* utilizes the same genes to
859 multiply within *Acanthamoeba castellanii* and human macrophages. *Infect Immun*
860 67, 2117-2124.
- 861 Sexton, J.A., Pinkner, J.S., Roth, R., Heuser, J.E., Hultgren, S.J., and Vogel, J.P. (2004). The
862 *Legionella pneumophila* PilT homologue DotB exhibits ATPase activity that is critical
863 for intracellular growth. *J Bacteriol* 186, 1658-1666.
- 864 Sharma, S., Skowronek, A., and Erdmann, K.S. (2015). The role of the Lowe syndrome
865 protein OCRL in the endocytic pathway. *Biol Chem* 396, 1293-1300.
- 866 Shi, J., Zhao, Y., Wang, K., Shi, X., Wang, Y., Huang, H., Zhuang, Y., Cai, T., Wang, F., and Shao,
867 F. (2015). Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell
868 death. *Nature* 526, 660-665.
- 869 Swan, L.E., Tomasini, L., Pirruccello, M., Lunardi, J., and De Camilli, P. (2010). Two closely
870 related endocytic proteins that share a common OCRL-binding motif with APPL1.
871 *Proc Natl Acad Sci U S A* 107, 3511-3516.
- 872 Swanson, M.S., and Isberg, R.R. (1995). Association of *Legionella pneumophila* with the
873 macrophage endoplasmic reticulum. *Infect Immun* 63, 3609-3620.
- 874 Tilney, L.G., Harb, O.S., Connelly, P.S., Robinson, C.G., and Roy, C.R. (2001). How the parasitic
875 bacterium *Legionella pneumophila* modifies its phagosome and transforms it into
876 rough ER: implications for conversion of plasma membrane to the ER membrane. *J*
877 *Cell Sci* 114, 4637-4650.
- 878 Toulabi, L., Wu, X., Cheng, Y., and Mao, Y. (2013). Identification and structural
879 characterization of a *Legionella* phosphoinositide phosphatase. *J Biol Chem* 288,
880 24518-24527.
- 881 Tsujishita, Y., Guo, S., Stolz, L.E., York, J.D., and Hurley, J.H. (2001). Specificity determinants
882 in phosphoinositide dephosphorylation: crystal structure of an archetypal inositol
883 polyphosphate 5-phosphatase. *Cell* 105, 379-389.
- 884 Vicinanza, M., Di Campli, A., Polishchuk, E., Santoro, M., Di Tullio, G., Godi, A., Levchenko, E.,
885 De Leo, M.G., Polishchuk, R., Sandoval, L., *et al.* (2011). OCRL controls trafficking
886 through early endosomes via PtdIns4,5P(2)-dependent regulation of endosomal
887 actin. *EMBO J* 30, 4970-4985.
- 888 Vogel, J.P., Andrews, H.L., Wong, S.K., and Isberg, R.R. (1998). Conjugative transfer by the
889 virulence system of *Legionella pneumophila*. *Science* 279, 873-876.
- 890 Zhu, W., Banga, S., Tan, Y., Zheng, C., Stephenson, R., Gately, J., and Luo, Z.Q. (2011).
891 Comprehensive identification of protein substrates of the Dot/Icm type IV
892 transporter of *Legionella pneumophila*. *PLoS One* 6, e17638.
- 893

894
895

896

Figure 1






Figure 2


A



B



C



D




Figure 3




Figure 4




Figure 5




Figure 6









Figure 7




Supp. Figure S1



Supp. Figure S2



Supp. Figure S3



Supp. Figure S4

